Arpida's Iclaprim MAA Accepted for Review By European Medicines Agency
Posted on: Thursday, 21 August 2008, 09:01 CDT
Arpida has announced that the European Medicines Agency has accepted for review its marketing authorization application for intravenous iclaprim.
Arpida is seeking approval of intravenous iclaprim in the EU for the treatment of complicated skin and soft tissue infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate with potent bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and an extended range of important pathogens.
The iclaprim marketing authorization application (MAA) contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (Assist-1 and Assist-2, in which approximately 1,000 patients were treated). Patients enrolled in the Phase III trials exhibited a high incidence of MRSA as causative pathogen.
In both of these two independent Phase III trials, intravenous iclaprim achieved the pre-specified primary endpoint of non-inferiority as compared to linezolid. In the studies, iclaprim was well-tolerated with a safety profile which compared favorably with the comparator in the treatment of patients with cSSTI.
In addition to the cSSTI indication, intravenous iclaprim is also being developed for the treatment of patients with hospital-acquired pneumonia, ventilator-associated pneumonia or healthcare-associated pneumonia suspected or confirmed to be due to Gram-positive pathogens.
Source: Datamonitor
Related Articles
- Chest Ultrasound As Useful As Chest CT In The Eval Of Pediatric Patients With Complicated Pneumonia
- AEterna Zentaris Completes Patient Recruitment for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
- NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
- AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program With Cetrorelix in Benign Prostatic Hyperplasia
- FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head; Patient-Specific Stem Cell Trial to Address Unmet Medical Need
- Viventia Biotech Initiates Patient Treatment for Vicinium(TM) Phase II Bladder Cancer Trial
- Cobalis Says Patient Input Completed in Trial
- Immtech Begins Pneumocystis Pneumonia Trial
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
- GelStat Corporation Completes Patient Enrollment in Clinical Trial of GelStat Migraine in Triptan Users
 |
 |
User Comments (0)
RSS Feeds